<DOC>
	<DOCNO>NCT01534208</DOCNO>
	<brief_summary>ZA-300 meant determine safety profile Androxal ( enclomiphene citrate ) men secondary hypogonadism .</brief_summary>
	<brief_title>Safety Study Enclomiphene Citrate Treatment Men With Secondary Hypogonadism</brief_title>
	<detailed_description>This study phase III , open label safety study six month active dosing period . All subject start 12.5 mg Androxal titrate 25 mg need . Safety assess physical visual acuity exam , slit lamp eye exam , clinical laboratory test adverse event reporting .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Secondary hypogonadal male age 18 65 2 . Men currently use topical testosterone product washout least 7 day Visit 1 . 3 . All clinical laboratory test within normal range ( clinically significant deviation laboratory result require approval sponsor ) 4 . Previously concurrently diagnose secondary hypogonadism confirm morning testosterone level &lt; 350 ng/dL men age &lt; 55 &lt; 300ng/dl men age 5565 5 . LH &lt; 15mIU/mL ( Visit 1 ) 6 . Ability complete study compliance protocol 7 . Ability understand provide write informed consent . 1 . Use injectable pelleted testosterone within 6 month prior study ( men currently topical testosterone product may enrol study 7day washout period ) . 2 . Use testosterone injection , spironolactone , cimetidine , Clomid , 5αreductase inhibitor , hCG , androgen , estrogen , anabolic steroid , DHEA , herbal hormone product study 3 . Use Clomid past year 4 . Uncontrolled hypertension base Investigator 's assessment baseline . Subjects treat Type II diabetes allow study . 5 . A hematocrit ≥ 51 % hemoglobin ≥ 17 g/dL 6 . Clinically significant abnormal finding screen examination , base Investigator 's assessment . 7 . Use investigational drug product , participation drug medical device research study within 30 day prior receive study medication . 8 . Known hypersensitivity Clomid 9 . Symptomatic cataract ( nuclear sclerosis cataract cortical cataract grade &gt; 2 base 04 scale trace posterior subcapsular cataract ) 10 . Any condition opinion investigator would interfere participant 's ability provide inform consent , comply study instruction , possibly confound interpretation study result , endanger participant take part study 11 . Irreversibly infertile compromise fertility ( cryptorchism , Kallman Syndrome , primary hypogonadism , tumor pituitary ) 12 . Current history breast cancer 13 . Current history prostate cancer suspicion prostate disease unless rule prostate biopsy , PSA &gt; 3.6 14 . Presence history know hyperprolactinemia without tumor 15 . Chronic use medication use glucocorticoid 16 . Chronic use narcotic 17 . Subjects know positive HIV 18 . End stage renal disease 19 . Subjects cystic fibrosis ( mutation CFTR gene ) 20 . Enrollment previous Androxal study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>